Cannabis
Gaps and uncertainty: how cannabis legalization is progressing in Mexico
Cannabis regulation in Mexico is among the top legislative priorities of 2020. With respect to the domestic drug policy, the regulation implies making therapeutic methods of cannabis available, which would be a way to end the stigmatization of the consumer. The deadline for senators to approve recreational cannabis legislation in Mexico is approaching as well.
In April 2016, former Mexican President Enrique Peña Nieto presented a reform initiative to decriminalize cannabis use to the Mexican Senate. Almost four years later, legal gaps and uncertainty have prevented it from moving forward.
Despite the fact that various legal initiatives have been presented to the Plenary to regulate cannabis consumption, one of which came from Olga Sánchez, Minister of the Internal Affairs, there is still no agreement.
The latest CBD & Cannabis updates are now at your fingertips, with notifications and fresh information offered by our companion CBD News App.
Legislation and decriminalization
The initiative presented by Sánchez suggests that a person can carry up to 30 grams of the cannabis plant. However, several analysts emphasized that regulation is needed. A study by the Center for Social Studies and Public Opinion of the Lower House found that there is no certainty for regulated consumption.
“If the reform initiative is approved as proposed by the Executive, the phenomenon of recreational use of cannabis will be partially addressed, since decriminalizing possession implicitly means that a consumer cannot be prosecuted. However, there are no certainties for its consumption, that is, no one carries cannabis to avoid consuming it,” was stated in the document.
Despite this, people like Sánchez Cordero claimed that a citizen has the right to carry the cannabis substance based on international practices that decriminalize consumption.
Small progress
The proposal promotes the implementation of cannabis clubs under a scheme of registration and control of cultivation, where quality controls can be established for the cannabis plants, which will guarantee the rights of non-consumers.
With respect to the approach of the domestic drug policy, the regulation implies making the therapeutic methods of cannabis available, while it could be a way to end the stigmatization of the consumer.
It is also believed that, with this measure, it will be possible to address and even reduce the alarming consumption in children under 14, as well as reduce the figure of 30% of teenagers who start consuming before reaching adulthood.
Legal gaps
It is worth noting that the deadline for senators to approve recreational cannabis legislation in Mexico is coming up, so the controversy is still in the air and public opinion is divided.
A survey conducted by the Belisario Dominguez Institute of the Mexican Senate at the end of 2019 revealed that the opinions of Mexican society are polarized, since 45.2% are in favor of approving this reform, while 42.7% reject the measure.
The interviews revealed that 5.4% of the respondents were in favor of medical use, but not for recreational purposes, while 66% said yes to the initiative to regulate medical cannabis.
As far as medical regulation is concerned, those interviewed said that it can be used to cure illnesses: 15% said that it will allow violence to be reduced by taking power away from drug trafficking, and 10% indicated that it is consumed in the same way.
Poorly regulated cannabis
It should be noted that legislators are discussing the risks involved in mishandling the regulation of cannabis. Such is the case of market monopolization that could be carried out by organized crime, having third parties as a facade .
Otherwise, former President Vicente Fox said in an interview with Publimetro Colombia that cannabis regulation can reduce violence, generate jobs and attract investment.
It is worth noting that the Spanish newspaper El Pais conducted a recount of the law initiatives presented for the regulation of cannabis in Mexico, which are more than 70 so far.
__
(Featured image by Jezael Melgoza via Unsplash)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in NACION CANNABIS, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
-
Biotech5 days ago
Sanofi Injects 40 Million Euros to Strengthen Its Production in France
-
Markets2 weeks ago
Markets Surge on Trump Victory—But Can Overvaluation and Recession Risks Stall the Rally?
-
Crypto3 days ago
Bitcoin ETF Options Debut in the U.S.: Is a New All-Time High on the Horizon?
-
Biotech2 weeks ago
Laminar Pharma Raises 5.9 Million in a New Round of Financing